The new cancer treatment also attracts tumours directly.
Tracy Robson and her research team at Queen’s, in collaboration with researchers at Almac Discovery, developed a new drug to disrupt the tumour blood supply.
Almac Discovery is developing the drug candidate and expects to initiate clinical trials within the next year.
Queen’s School of Pharmacy professor Tracy Robson said understanding the anti-angiogenic potential of the natural protein, FKBPL, they have been able to develop small peptide-based drugs that could be delivered to prevent tumour growth by cutting off their blood supply. This is effective in models of prostate and breast cancer.